ruboxistaurin

Subscribe to Selected New Research on ruboxistaurin

37 relevant articles (5 outcomes, 16 trials/studies) found for this Bio-Agent

Description: inhibits protein kinase C beta; structure in first source

Also Known As:

13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione; Arxxant; LY 333531; LY-333531; Lilly brand of ruboxistaurin mesilate hydrate; ruboxistaurin mesilate hydrate

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

2-Ring Heterocyclic Compounds

Indoles: 69

ruboxistaurin: 37

Organic Chemicals: 40

Carboxylic Acids: 63

Acyclic Acids

Dicarboxylic Acids: 73

Experts

1.	McGill, Janet B: 2 articles (07/2007 - 04/2007)
2.	Tuttle, Katherine R: 2 articles (07/2007 - 04/2007)
3.	Haney, Douglas J: 2 articles (07/2007 - 04/2007)
4.	Anderson, Pamela W: 2 articles (07/2007 - 04/2007)
5.	Bastyr, Edward J: 2 articles (04/2007 - 08/2005)
6.	Vinik, Aaron I: 2 articles (04/2007 - 08/2005)
7.	Aiello, Lloyd Paul: 2 articles (12/2006 - 10/2005)
8.	Delaney-Robinson, Carol: 1 article (03/2008)
9.	Yue, Dennis K: 1 article (03/2008)
10.	Molyneaux, Lynda: 1 article (03/2008)

Related Diseases

1.	Diabetic Retinopathy (Retinopathy, Diabetic) 11/13/2008 - "Based on secondary analyses of clinical trials in patients with diabetic retinopathy or neuropathy, ruboxistaurin appears safe and may also prevent onset of DKD" 01/01/2007 - "This phase III, randomised, double-blind, multidose study in 252 patients with type 1 and type 2 diabetes receiving ruboxistaurin or placebo for 3-4 years evaluated the safety of the agent and its effect on progression of diabetic retinopathy, moderate vision loss and sustained moderate vision loss" 01/01/2007 - "Previously, results of the PKC-Diabetic Retinopathy Study (PKC-DRS) showed that ruboxistaurin at a dose of 32 mg/day has potential to reduce the risk of moderate vision loss especially in patients with diabetic macular oedema" 01/01/2007 - "from a phase III, 3-year study of ruboxistaurin in patients with moderate to severe diabetic retinopathy showed that ruboxistaurin markedly reduced the risk of sustained vision loss compared with placebo" 12/01/2007 - "Ruboxistaurin shows promise as an oral treatment for diabetic retinopathy" Get all the results and reference details, order at left...
2.	Macular Edema 10/01/2005 - "Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema." 12/01/2006 - "Initial laser treatment for macular edema was 26% less frequent in eyes of ruboxistaurin-treated patients (P = 0.008)" 12/01/2006 - "When clinically significant macular edema was >100 microm from the center of the macula at baseline, ruboxistaurin treatment was associated with less frequent progression of edema to within 100 microm (68% vs. 50%, P = 0.003)" 03/01/2007 - "OBJECTIVE: To evaluate the safety and efficacy of orally administered ruboxistaurin (RBX) as a mesylate salt in patients with diabetic macular edema (DME)" 10/01/2005 - "PURPOSE: The purpose of the study was to investigate the effect of orally administered ruboxistaurin (RBX, LY333531), a selective protein kinase C beta inhibitor, on the permeability of the blood-retinal barrier in patients with diabetic macular edema" Get all the results and reference details, order at left...
3.	Low Vision (Subnormal Vision) 12/01/2006 - "CONCLUSION: Oral ruboxistaurin treatment reduced vision loss, need for laser treatment, and macular edema progression, while increasing occurrence of visual improvement in patients with nonproliferative retinopathy." Get all the results and reference details, order at left...
4.	Kidney Diseases (Kidney Disease) 11/01/2005 - "OBJECTIVE: Ruboxistaurin selectively inhibits protein kinase C-beta and ameliorates kidney disease in animal models of diabetes" Get all the results and reference details, order at left...
5.	Peripheral Nervous System Diseases (PNS Diseases) 01/01/2007 - "Under the terms of the agreement, Eli Lilly Japan and Takeda will jointly develop ruboxistaurin in Japan, will file an NDA for diabetic peripheral neuropathy and diabetic retinopathy, and subsequently will market the drug in Japan" 03/01/2008 - "PURPOSE: This article aims to study the effects of ruboxistaurin (RBX) on skin microvascular blood flow (SkBF) and evaluate the relationship between endothelial and neural control of SkBF in patients with diabetic peripheral neuropathy (DPN)" 04/01/2007 - "A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy." 03/01/2008 - "Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin." 10/01/2007 - "OBJECTIVE: The purpose of this study was to evaluate the change in neuropathy symptoms and disease progression in placebo-administered patients from two 1-year studies in which the impact of ruboxistaurin (RBX) in mild diabetic peripheral neuropathy (DPN) was tested" Get all the results and reference details, order at left...
27 Diseases and 37 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	protein kinase C beta
2.	Protein Kinase C
3.	Mesylates (Mesylate)
4.	NAD (NADH)
5.	dimethylethylsilylimidazole
6.	Sodium
7.	CDP870
8.	tiotropium (Spiriva)
9.	Thiazolidinediones
10.	Succinic Acid (Succinate)
288 Drugs and Important Bio-Agents and 29 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Stents
2 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>